Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
Current TAP Partner
WATERTOWN, Mass., June 09, 2023 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced new data demonstrating that its oncology programs KT-333 and KT-413 continue to demonstrate substantial target knockdown in ongoing Phase 1a dose escalation clinical trials, with no dose limiting toxicities (DLTs) observed. The data were shared in the online abstract book of the International Conference on Malignant Lymphoma (ICML), taking place from June 13-17, 2023, in Lugano, Switzerland, and reflect a data cut-off date of February 3, 2023. On June 14, a KT-333 poster will be released at ICML and presented on June 16. Kymera will share updated results from both programs in conjunction with the poster release on June 14.
Highlights of KT-333
KT-333 is designed as a potent degrader of STAT3 being developed for the treatment of STAT3-dependent hematological malignancies and solid tumors. As of the abstract cut-off date of February 3, 2023, 7 patients had been treated in the first 2 dose levels (DL1 and DL2) of the trial, including patients with solid tumors as well as peripheral T-cell lymphoma and cutaneous T-cell lymphoma:
- Plasma PK results were in line with the modeled predictions.
- PD data in peripheral blood mononuclear cells (PBMC) demonstrated dose-dependent and sustained STAT3 degradation after dosing.
- Most common adverse events were Grade 1 and 2 and included constipation, fatigue, abdominal pain, dizziness, and nausea. No DLTs were observed.
- Accrual is ongoing, and analyses from additional patients will be presented at ICML.
Highlights of KT-413
KT-413 is a novel heterobifunctional degrader targeting both IRAK4 and the IMiD substrates Ikaros and Aiolos in development for the treatment of MYD88-mutant B-cell malignancies. As of the abstract cut-off date of February 3, 2023, 3 patients had been treated in the first 3 dose levels of the trial, including transformed activated B-cell-like (ABC)-diffuse large B-cell lymphoma (DLBCL), follicular lymphoma and marginal zone lymphoma, all of which were MYD88 wild-type:
- Plasma PK results were in line with the modeled predictions.
- Dose-dependent, sustained target knockdown in PBMC was observed.
- Most common adverse events across all three dose levels were Grade 1 and 2 fatigue and pyrexia. No DLTs were observed.
- Accrual is ongoing, and analyses from additional patients will be shared in an update from Kymera in conjunction with the KT-333 ICML update.
As previously announced, Kymera intends to present data evaluating anti-tumor activity for both KT-333 and KT-413 later this year.